Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner
- Posted on February 25, 2026
- By CNBC
- 4 Views
Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
